Figure 1.
Outcomes ofpatients with KMT2Arenrolled in St. Jude Total Therapy 16 Study. (A) Treatment outcome for all patients <1 year of age on study (N = 12). See Table 1 for clinical and biological features. 5-year OS, 5-year EFS, and 5-year cumulative incidence of relapse are shown. Ninety-five percent of confidence intervals are indicated in the table. There was no statistically significant difference in outcomes when comparing infants with KMT2Ar and without KMT2Ar. (B) Treatment outcome for all patients with KMT2Ar on study (N = 19 KMT2Ar ≥ 1 year of age and N = 9 KMT2Ar <1 year of age). Ninety-five percent of confidence intervals are indicated in the table. There was a trend toward inferior OS and EFS in infants with KMT2Ar which did not reach statistical significance. There is no difference in CIR for infants with KMT2Ar and older patients.

Outcomes ofpatients with KMT2Arenrolled in St. Jude Total Therapy 16 Study. (A) Treatment outcome for all patients <1 year of age on study (N = 12). See Table 1 for clinical and biological features. 5-year OS, 5-year EFS, and 5-year cumulative incidence of relapse are shown. Ninety-five percent of confidence intervals are indicated in the table. There was no statistically significant difference in outcomes when comparing infants with KMT2Ar and without KMT2Ar. (B) Treatment outcome for all patients with KMT2Ar on study (N = 19 KMT2Ar ≥ 1 year of age and N = 9 KMT2Ar <1 year of age). Ninety-five percent of confidence intervals are indicated in the table. There was a trend toward inferior OS and EFS in infants with KMT2Ar which did not reach statistical significance. There is no difference in CIR for infants with KMT2Ar and older patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal